ENZO BIOCHEM reports 2018 executive compensation

CEO Elazar Rabbani receives $1.5M

ENZO BIOCHEM reported fiscal year 2018 executive compensation information on November 21, 2018.

In 2018, five executives at ENZO BIOCHEM received on average a compensation package of $836,968, a 3% decrease compared to previous year.

Average pay of disclosed executives at ENZO BIOCHEM

Elazar Rabbani, Chief Executive Officer, received $1,476,672 in total, which decreased by 4% compared to 2017. 41.38% of Rabbani's compensation, or $611,000, was in salary. Rabbani also received $500,000 in non-equity incentive plan, $137,340 in option awards, $44,200 in stock awards, as well as $184,132 in other compensation.

Barry W. Weiner, Chief Financial Officer, received a compensation package of $1,246,875, which decreased by 1% compared to previous year. 43.47% of the compensation package, or $542,000, was in salary.

Bruce A. Dey, Vice President of Sales, Enzo Clinical Labs, earned $496,496 in 2018, a 12% decrease compared to previous year.

James M. O'Brien, Executive Vice President of Finance, received $494,722 in 2018, which decreases by 1% compared to 2017.

Dieter Schapfel, Chief Technology Officer, earned $470,076 in 2018, a 4% increase compared to previous year.

ENZO BIOCHEM's fiscal year ends on July 31.